NRC Form 374A
(5-84)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
34-01710-05

Docket or Reference number
030-02685

Amendment No. 31

The Toledo Hospital
2142 N. Cove Blvd.
Toledo, OH 43606

In accordance with letter dated June 13, 1985, License Number 34-01710-05 is amended as follows:

Items 6., 7., 8. and 9. are amended to add:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
J. Gadolinium-153	J. Sealed sources (Gulf Nuclear Model GD-1 contained in a Lunar Radiation Corp. lead-lined brass source holder)	J. 2 curies (2 sources not to exceed 1 curie each)

9. Authorized Use

J. One source to be used as a component of Lunar Radiation Corporation Model DP3 Spine/Femur Scanner for determining human bone mineral content. One source in its shipping container to be in possession of the licensee as necessary for replacement in the scanner.

Conditions 12. and 19. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

C. Douglass Ford, M.D.	Groups I, II, III, IV and V Xenon-133 Technetium-99m reference standard Gadolinium-153 In vitro studies
William F. Jeffries, M.D.	Groups I, II, III, IV and V Xenon-133 Technetium-99m reference standard Gadolinium-153 In vitro studies
William K. Mueller, M.D.	Groups IV and VI
William D. Eggleston, M.D.	Group VI

COPY 2

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
34-01710-05

Docket or Reference number
030-02685

Amendment No. 31

Ralph R. Dobelbower, Jr., M.D.	Groups IV, V and VI
Steven R. Zeidner, M.D.	Group VI
Henry R. Silverman III, M.D.	Technetium-99m as a prepared radiopharmaceutical for cardiac imaging and studies of cardiac function
Shui Chin Chen, Ph.D.	In vitro studies
Phillip J. Silverman, M.D.	Groups I, II, III and IV
Michael R. Hay, M.D.	Groups I, II and III Xenon-133 Iodine-131 for treatment of thyroid carcinoma In vitro studies
Allan S. Kaufman, M.D.	Groups I, II and III Xenon-133 In vitro studies
Daniel Singer, M.D.	Groups I, II, III and IV Xenon-133 Iodine-131 for treatment of thyroid carcinoma Gadolinium-153
William G. Novak, M.D.	Groups I, II and III Xenon-133
Harvey E. Muehlenbeck, M.D.	Groups I, II and III Xenon-133 Soluble phosphorus-32 for treatment of polycythemia vera, leukemia and bone metastases Iodine-131 for treatment of hyperthyroidism and cardiac dysfunction
Warren Nordin, M.D.	In vitro studies
Gerald W. Narsa, M.D.	Group VI
Chun Il Mah, M.D.	Group VI

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
34-01710-05

Docket or Reference number
030-02685

Amendment No. 31

19. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated February 9, 1983; letters dated March 15, 1984, June 5, 1985 (with attachments), October 30, 1984 and June 13, 1985; and ALARA Program dated February 9, 1983. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

Conditions 21., 22. and 23. are added:

21. A. (1) Sealed sources listed in Subitem 6.J. shall be tested for leakage and/or contamination at intervals not to exceed six months. In the absence of a certificate from a transferor indicating that a test has been made within six months prior to the transfer, a sealed source received from another person shall not be put into use until tested.

(2) Notwithstanding the periodic leak test required by this condition, any licensed sealed source is exempt from such leak tests when the source contains 100 microcuries or less of beta and/or gamma emitting material or 10 microcuries or less of alpha emitting material.

B. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. The test sample shall be taken from the sealed source or from the surfaces of the device in which the sealed source is permanently mounted or stored on which one might expect contamination to accumulate. Records of leak test results shall be kept in units of microcuries and maintained for inspection by the Commission.

C. If the test reveals the presence of 0.005 microcurie or more of removable contamination, the licensee shall immediately withdraw the sealed source from use and shall cause it to be decontaminated and repaired or to be disposed of in accordance with Commission regulations. A report shall be filed within five (5) days of the test with the U. S. Nuclear Regulatory Commission, Region III, 799 Roosevelt Road, Glen Ellyn, Illinois 60137, describing the equipment involved, the test results, and the corrective action taken.

D. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically authorized by the Commission or an Agreement State to perform such services.

22. Sealed sources listed in Subitem 6.J. shall not be opened or removed from their respective source holders by the licensee.

COPY

NRC Form 374A
*(5-84)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
34-01710-05

Docket or Reference number
030-02685

Amendment No. 31

23. Maintenance or repair of the Lunar Radiation Corporation Spine/Femur Scanner involving the device shutter or other components that may compromise the safety of the unit shall be performed only by the device manufacturer or by other persons specifically authorized by the Commission or an Agreement State to perform such services.

For the U.S. Nuclear Regulatory Commission

Original Signed
By B.J. Holt
Materials Licensing Section, Region III

Date July 25, 1985

COPY